The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.

Login to TechFinder » 

Simultaneous Stimulation and Recording of Electroactive Tissues


Stanford Reference:

11-260


Abstract


Stanford engineers have developed a novel stimulation technology for the pacing of cardiac cells and other electroactive tissues, which minimizes stimulation artifacts and electrode voltage. This all-electric technology provides unprecedented ability to record the tissue activity even during the stimulation, enabling detection of activity without blanking periods, and true closed-loop controlled stimulation. The technology is compatible with current stimulation delivery tools (microelectrode arrays, leads, catheters). Applications include in vitro experiments with microelectrode arrays (research, drug-screening), stimulation threshold-based assays, and power-optimized in vivo pacing based on closed-loop control.

Stage of Research
The inventors have demonstrated the technology with cardiomyocytes in vitro. They were able to reliably stimulate cells and simultaneously measure action potentials in the cell cultures.

Applications


  • In vitro electrophysiology - minimal artifacts from stimulus (no need for blanking or post processing), ability to measure the electrical activity even during the application of the stimulus.
  • Cell-based assays - real-time assessment of stimulation threshold and its modulation by drugs.
  • Pacemakers with in vivo closed-loop pacing - power optimized stimulation for pacemakers using measurement of tissue response to adjust stimulus in real-time, on a beat-by-beat basis.

Advantages


  • Minimum stimulation artifact - an electrical stimulation technology that does not interfere with native activity measurement, even allowing simultaneous recording.
  • Improved safety and reliability - lower electrode potentials reduces electrochemical reaction at electrodes, hence increases safety and reliability, especially for long-term use.
  • Compatibility - all-electric technology compatible with standard electrophysiology delivery systems.

Publications



Innovators & Portfolio



Date Released

 6/25/2013
 

Licensing Contact


Mona Wan, Associate Director
650-498-0902 (Business)
Login to Request Information

[-] Map/Timeline

91-041 NF-AT transcription system for screening of immunosuppressive drugs•The Fgl-5 cell line
91-042 NF-AT translocation as a site of therapeutic intervention
95-040 Green Fluorescent Protein (GFP) Mutants

more technologies

Related Keywords


Cardiac resynchronization   cardiac pacing   medical devices: cardiovascular   MEMS: bioMEMS   microelectrode array   screening: cellular assay   models of medical pathophysiology   cardiovascular device   ablation   arrhythmia   atrial arrhythmia   atrial fibrillation   cardiac ablation   cardiac rhythm management   cardiac tissue   Electrophysiology   electrical stimulation   pacemakers   cardiomyocyte   electrophysiologic monitoring   ventricular pacing   catheter ablation   radiofrequency ablation   
 

   

  

Also of Interest...
91-041 NF-AT transcription system for screening of immunosuppressive drugs•The Fgl-5 cell line
91-042 NF-AT translocation as a site of therapeutic intervention
95-040 Green Fluorescent Protein (GFP) Mutants

Recently Viewed...
S11-260 Simultaneous Stimulation and Recording of Electroactive Tissues